Results 201 to 210 of about 17,757 (259)

Phase Separation of NFIB Suppresses SLC3A2‐Mediated Ferroptosis in Castration‐Resistant Prostate Cancer

Advanced Science, Volume 13, Issue 26, 8 May 2026.
Castration‐resistant prostate cancer (CRPC) remains sensitive to ferroptosis, but its intrinsic resistance is poorly understood. Here, we identify NFIB as a master suppressor. SIRT7‐mediated NFIB acetylation drives its liquid–liquid phase separation, which promotes SLC3A2 transcription to inhibit ferroptosis.
Qiunuo Li, Danyang Chen, Yongzhen Xia, Yili Long, Nan Huang, Rongna Li, Mengting Shi, Mairehaba Kadier, Huafeng Luo, Xiaohui Chen, Hao Liu, Guanmin Jiang   +11 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

In utero exposure to medications and congenital eye anomalies. [PDF]

BMJ Open Ophthalmol
Mairesse R, Lepetit M, Dubucs C, Cifuentes EA, Damase-Michel C, Lacroix I.   +5 more
europepmc   +1 more source

Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation

Advanced Science, Volume 13, Issue 26, 8 May 2026.
ABSTRACT Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are ...
David J. Lundy, Zoe L. Chau, Sheng‐You Chen, Nanami Fujisawa, John J. Hill, Barnett M. Hsu, Joanne K. Liu, Karol W. Mai, James J. Lai   +8 more
wiley   +1 more source

Effect of Neoadjuvant Hormonal Therapy on Breast Conservation in Invasive Ductal Versus Lobular Carcinoma of the Breast: A Comparative Analysis. [PDF]

J Surg Oncol
Goldhaber NH, O'Keefe TJ, Longo L, Blair SL, Grossi S.   +4 more
europepmc   +1 more source

Nuclear Mechanotransduction Across the Metastatic Cascade: Decoding Spatiotemporal Heterogeneity in Cancer Dissemination

Advanced Science, Volume 13, Issue 25, 4 May 2026.
Tumor metastasis results from complex interactions between cancer cells and mechanical microenvironments. We propose a “nucleus‐centered, cross‐stage mechanical signal decoding” model, highlighting how nuclear mechanosensors interpret forces at different stages.
Linqi Song, Jingyang Liu, Xue Wang, Minpu Zhang, Changgang Sun   +4 more
wiley   +1 more source

First real-world evidence from the Emilia-Romagna region suggests tamoxifen protects breast cancer patients from COVID-19. [PDF]

Sci Rep
Bravaccini S, Nicolini F, Balzi W, Azzali I, Pasini L, Mazzotti L, Gaimari A, De Lucia A, Zurlo M, Maltoni R, Pirini F, Cortesi M, Zanoni M, Tumedei MM, Nanni O, Cerchione C, Sambri V, de Souza PB, Martinelli G, Mazza M.   +19 more
europepmc   +1 more source

Immunotherapy and Breast Reconstruction: Opportunities, Challenges, and Future Directions

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Immunotherapy is transforming breast cancer management, but it also presents new challenges for surgical and reconstructive practice. This review summarizes current evidence on immune checkpoint inhibitors, perioperative safety, and immune‐related adverse events, highlighting their impact on surgical timing, postoperative recovery, and ...
Shuang Li, Jianguo Wang, Yingjie Liu, Wenwu Cai, Weichang Zhang, Shengyun Li, Yunjian Zhang   +6 more
wiley   +1 more source

Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience. [PDF]

BMC Cancer
Baş O, İnci BK, Eroğlu İ, Efil SC, Kaya S, Tolunay PK, Şahin TK, Karaçin C, Yazıcı O, Şendur MAN, Öksüzoğlu BÖÇ, Aksoy S.   +11 more
europepmc   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source